Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype
Study Details
Study Description
Brief Summary
This is a two-part, Phase IIa, multicenter, 12-week, open-label study. Up to 56 participants with deletion Angelman Syndrome (AS) aged 5-17 years (inclusive) will be enrolled in the study.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
The study will have Part 1-dose confirmations and Part 2 with dose levels to be decided based on the cumulative PK, EEG, and safety data emerging from Part 1.
The dose levels for the first cohort of Part 2 will be decided based on the cumulative PK, EEG, and safety data emerging from Part 1.
Part 2 will explore the change in EEG beta-band power relative to baseline at Week 2, Week 4 (i.e., approximately 2 weeks after the start of the second dose), and at the end of the 12-week treatment period after daily administration of Alogabat.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Part 1 Adult Alogabat High Dose (aged 15-17) In Part 1 of the study, participants will receive age-adjusted dose 60 mg QD alogabat. |
Drug: 60 mg QD Alogabat
Participants aged 15-17 years or above receiving the adult 60 mg of alogabat dose.
I
|
| Experimental: Part 1 Age adjusted high dose (age 10-14) In Part 1 of the study, participants will receive age-adjusted dose 60 mg QD alogabat. |
Drug: 40 mg QD Alogabat
Participants aged 10-14 years receiving the equivalent of the adult 60 mg alogabat dose.
|
| Experimental: Part 1 Age Adjusted Low Dose (age 5-9) In Part 1 of the study, participants will receive age-adjusted dose 20 mg QD alogabat. |
Drug: 7 mg QD Alogabat
Participants aged 5-9 years receiving the equivalent of the adult 20 mg alogabat dose.
|
| Experimental: Part 2 Cohort 1 In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered. |
Drug: Part 2 Adult Alogabat High Dose (aged 15-17)
In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered.
|
| Experimental: Part 2 Cohort 2 In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered. |
Drug: Alogabat
In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered.
|
| Experimental: Part 2 Cohort 3 In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered. |
Drug: Alogabat
In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered.
|
| Experimental: Part 1 Optional Cohort If dose adjustments (e.g., increase or decrease in dose) are required, particularly due to uncertainty of the clearance estimates (e.g., due to high variability) or over-/underprediction of the pediatric clearance versus adult clearance, up to 8 additional participants may be recruited in any of the 3 age-groups in order to confirm the exposure equivalence prior to selecting doses and proceeding to Part 2. |
Drug: Alogabat
If dose adjustments (e.g., increase or decrease in dose) are required, particularly due to uncertainty of the clearance estimates (e.g., due to high variability) or over-/underprediction of the pediatric clearance versus adult clearance, up to 8 additional participants may be recruited in any of the 3 age-groups in order to confirm the exposure equivalence prior to selecting doses and proceeding to Part 2.
|
Outcome Measures
Primary Outcome Measures
- Age-group based ratio of plasma PK parameter, area under the concentration-time curve (AUC) [Up to 12 Weeks]
In Part 1 only. Age-group based ratio of plasma PK parameters in pediatric participants with AS versus data collected from adult healthy volunteers and participants with ASD (area under the concentration-time curve [AUC])
- Age-group based ratio of plasma PK parameter, apparent clearance (CL/F) [Up to 12 Weeks]
In Part 1 only. Age-group based ratio of plasma PK parameters in pediatric participants with AS versus data collected from adult healthy volunteers and participants with ASD (apparent clearance [CL/F])
- Change from baseline to Week 2, 4, and 12 in resting state EEG power in the beta band [Week 2, 4, and 12]
In Part 2 only
Secondary Outcome Measures
- Plasma pharmacokinetic parameter of alogabat, maximum concentration (Cmax) [Up to 12 Weeks]
In Part 1 and 2. Plasma pharmacokinetic parameter of alogabat maximum concentration (Cmax) as derived using a population-pharmacokinetic (popPK) model
- Plasma pharmacokinetic parameters of alogabat area under the concentration-time curve (AUC) [Up to 12 Weeks]
In Part 1 and 2. Plasma pharmacokinetic parameter of alogabat area under the concentration-time curve (AUC) as derived using a population-pharmacokinetic (popPK) model
- Plasma pharmacokinetic parameter of alogabat, apparent clearance (CL/F) [Up to 12 Weeks]
In Part 1 and 2. Plasma pharmacokinetic parameter of alogabat apparent clearance (CL/F) derived using a population-pharmacokinetic (popPK) model
- Incidence and severity of adverse events (AEs) and serious adverse events (SAEs). [Up to 18 Weeks]
In Part 1 and 2. Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
- Incidence of treatment discontinuations due to AEs [Up to 18 Weeks]
Incidence of treatment discontinuations due to AEs in Part 1 and 2
- Incidence of daytime sleepiness assessed with the Karolinska Sleepiness Scale (KSS), and incidence of sudden onset of sleep assessed with somnolence diary [Up to 21 Weeks]
Incidence of daytime sleepiness assessed with the Karolinska Sleepiness Scale (KSS), and incidence of sudden onset of sleep assessed with somnolence diary in Part 1 and 2.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Clinical diagnosis of AS and a genetic subtype of deletion on the maternally inherited chromosome 15q11q13 confirmed by a historical molecular diagnosis. The deletion must include UBE3A, GABRB3, GABRA5, and GABRG3 genes, and be less than 7 Mb in size.
-
Body mass index (BMI) below the 97th percentile and above the 3rd percentile for the same age and sex
-
The reliability of sexual abstinence for male and/or female enrollment eligibility needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of preventing drug exposure.
-
Female participants:
A female participant is eligible to participate if she is not pregnant, not breastfeeding, and non-childbearing or remain abstinent and/or Hormonal contraceptive methods must be supplemented
-Male participants: Male contraception is not required in this study because of the minimal seminal dose transmitted through sexual intercourse
Exclusion Criteria:
-
A molecular diagnosis of AS with genotypic classification of any type besides the molecular diagnosis as specified in Inclusion Criterion
-
Concurrent cardiovascular disease considered not well controlled by drug treatment, including participants with clinically significant hypertension, bradycardia and arrhythmias, myocardial infarction within 12 months of screening or uncompensated heart failure
-
Confirmed clinically significant abnormality on 12-lead ECG, including:
-
a QTcF of >/= 450 ms (based on the average of 3 consecutive measurements) for participants older than 10 years old
-
a QTcB of >/= 450 ms (based on the average of 3 consecutive measurements) for participants up to, and including, the age of 10 years old
-
Congenital heart diseases not treated and congenital QTc prolongation or family history of Long QT Syndrome
-
Medical history of malignancy if not considered cured or if occurred within the last 5 years with the exception of fully excised non-melanoma skin cancers or in-situ carcinoma of the cervix that has been successfully treated
-
Concomitant disease, condition, or treatment that would either interfere with the conduct of the study or pose an unacceptable risk to the participant in the opinion of the Investigator.
-
Known active or uncontrolled bacterial, viral, or other infection (excluding fungal infections of nail beds) or any major episode of infection or hospitalization (relating to the completion of the course of antibiotics) within 6 weeks prior to the start of drug administration. Rescreening is allowed once the infection is cured and if the rescreening criteria are met.
-
Any concomitant condition that might interfere with the clinical evaluation of AS and that is not related to AS
-
Known history of human immunodeficiency virus (HIV) or hepatitis B virus (HBV) or hepatitis C virus (HCV)
-
Hospitalization for any major medical or surgical procedure involving general anesthesia within 12 weeks of Screening or planned during the study. Rescreening is allowed not earlier than 12 weeks after the surgery and if the rescreening criteria are met.
-
Use of prohibited medications within 6 weeks or 5 half-lives (t1/2) prior to start of study medication on Day 1 (whichever is longer)
-
Clinically significant loss of blood within 3 months prior to screening defined by participant age and weight per recommendations from Duke University (2012)
-
Participation in an investigational drug study within 6 weeks or 5 times the t1/2 of the investigational molecule (whichever is longer) prior to randomization or participation in a study testing an investigational medical device within 6 weeks prior to randomization or if the device is still active. Concurrent or planned concurrent participation in any clinical study (including observational and non-interventional studies) without approval of the Investigator.
-
Previous participation in a cellular therapy, gene therapy, or gene editing clinical study
-
Clinically significant vital sign or ECG abnormalities at Screening
-
Confirmed clinically significant abnormality in hematological, chemistry or coagulation laboratory parameters
-
Uncorrected hypokalemia or hypomagnesaemia
-
Positive test result at screening for hepatitis B surface antigen (HBsAg), HCV (untreated), or HIV-1/2. Participants with HCV who have been successfully treated and who test negative for HCV RNA may be considered eligible for entry into the study.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Hoffmann-La Roche
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- BP41315
- 2022-501844-14-00